Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

The requested reference [07725c1feb5b1c52657faabc92b93a3e02fc0d49] no longer exists in our database. It has been replaced by the current reference: [6afaaeb805a0e7e0fd77b2070dc8bf22f379f400]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
PERT-1/12102020 is a double-blind randomized single-center clinical trial comparing pharmacokinetics, immunogenicity and safety profiles of Pertuzumab (manufactured by Mabscale, LLC) compared to Perjeta® in healthy men. The purpose of the study is to demonstrate equivalence of pharmacokinetics, immunogenicity and safety of Pertuzumab (manufactured by Mabscale, LLC) to Perjeta®.
Epistemonikos ID: c48951ebf61536f0dc4d63ec409f190797989b4a
First added on: Feb 19, 2024